Major depressive disorder is an extremely debilitating condition affecting millions of people
worldwide. Nevertheless, currently available antidepressant medications still have important …

A debilitating mental disorder, major depressive disorder is a leading cause of global
disease burden. Existing antidepressant drugs are not adequate for the majority of …

Ketamine is a versatile agent primarily utilized as a dissociative anesthetic, which acts by
blocking the excitatory receptor N-methyl-d-aspartate receptor (NMDA). It functions to inhibit …

Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate
(NMDA) receptors. The discovery of its rapid antidepressant effects in patients with …

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-
based antidepressant drugs are a primary line of treatment for this mental disorder, although …

The molecular mechanisms underlying major depressive disorder remain poorly
understood, and current antidepressant treatments have many shortcomings. The recent …

Over the last decade, numerous controlled studies have consistently described rapid, robust,
and relatively sustained antidepressant response rates associated with single-dose …

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-
resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of …

Major depressive disorder affects millions of people and leads to debilitating symptoms.
Although conventional antidepressants have been available and are often beneficial, they …

Recent reports of a rapid antidepressant effect of the glutamate N‐methyl‐d‐aspartate
(NMDA) receptor antagonist ketamine, even in treatment‐resistant populations, have …